Clinical Trials
38 trialsNCT04235257 2026-05-05
Intradermal, Fractional Dose of HPV Vaccines:
University of Washington
Phase 4 Active not recruiting
NCT05291871 2026-05-05
Immunogenicity of Fractional Dose of the HPV Vaccines
University of Washington
Phase 4 Active not recruiting
NCT05266898 2025-04-18
AGO-Gard
Louisiana State University Health Sciences Center in New Orleans
Phase 4 Recruiting
NCT01824537 2025-03-19
TRAP-HPV
McGill University
Phase 4 Completed
NCT05202860 2025-01-22
VAXAK
Bispebjerg Hospital
Phase 2 Active not recruiting
NCT06686043 2024-11-13
HPV-VIM
Baylor College of Medicine
Phase 2 Recruiting
NCT03489707 2024-11-12
The Prevent Anal Cancer Self-Swab Study
Medical College of Wisconsin
Phase NA Completed
NCT03629886 2024-03-15
Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study
GlaxoSmithKline
Phase 4 Completed
NCT04774887 2024-02-23
ERADICATING CERVICAL CANCER IN KENYA
Indiana University
Phase NA Completed
NCT06207175 2024-01-23
A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine
Beijing Health Guard Biotechnology, Inc
Phase 3 Unknown
NCT02865135 2024-01-11
Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT02740790 2023-04-13
Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 Vaccine in Healthy Females
Shanghai Zerun Biotechnology Co.,Ltd
Phase 2 Completed
NCT03900572 2023-04-13
A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine
Shanghai Zerun Biotechnology Co.,Ltd
Phase 1 Completed
NCT05694728 2023-01-23
A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine
Beijing Health Guard Biotechnology, Inc
Phase 2 Completed
NCT05680454 2023-01-17
A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine
Beijing Health Guard Biotechnology, Inc
Phase 1 Completed
NCT05672966 2023-01-06
Phase I Clinical Trial of a Candidate HPV Vaccine
Wuhan BravoVax Co., Ltd.
Phase 1 Unknown
NCT05668572 2023-01-04
A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine
Beijing Health Guard Biotechnology, Inc
Phase 3 Unknown
NCT05662020 2022-12-27
A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China
Beijing Health Guard Biotechnology, Inc
Phase 3 Active not recruiting
NCT05173324 2022-08-03
H2VICTORY
International Agency for Research on Cancer
Phase 3 Not yet recruiting
NCT01928225 2020-06-24
Randomized, Double Blind Trial of the Quadrivalent HPV Vaccine to Improve Responses to LEEP Treatment of Cervical HSIL
University of Witwatersrand, South Africa
Phase 2 Completed
NCT01735006 2020-02-24
Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine
Xiamen University
Phase 3 Completed
NCT00231413 2019-12-12
Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.
GlaxoSmithKline
Phase 2 Completed
NCT00309166 2018-09-17
Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males.
GlaxoSmithKline
Phase 2 Completed
NCT03085381 2018-09-14
A Phase I Study of Quadrivalent HPV Recombinant Vaccine
Shanghai Bovax Biotechnology Co., Ltd.
Phase 1 Completed
NCT00541970 2018-08-17
Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs
GlaxoSmithKline
Phase 1 Completed
NCT00578227 2018-08-17
Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects
GlaxoSmithKline
Phase 3 Completed
NCT00652938 2018-08-17
Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects
GlaxoSmithKline
Phase 3 Completed
NCT01984697 2018-08-08
V503-010
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00552279 2018-06-25
Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age
GlaxoSmithKline
Phase 3 Completed
NCT01909752 2017-07-06
Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer
UbiVac
Phase 2 Completed
NCT00496626 2017-04-17
An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01356823 2016-01-05
Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine
Xiamen University
Phase 2 Completed
NCT01096134 2015-10-12
MDI
Jhpiego
Phase NA Completed
NCT00092521 2015-09-25
Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00501137 2015-04-10
BCGov-01
University of British Columbia
Phase 3 Completed
NCT00325130 2015-03-12
Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01034358 2012-10-23
Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease
Mayo Clinic
Phase 4 Completed
NCT01133509 2012-08-23
A Model for Implementation of Cervical Cancer Screening and HPV Vaccination the Emergency Department: a Pilot Study
Eastern Virginia Medical School
Phase NA Unknown